Purpose of the Procedure
- Detect residual cancer cells after surgery or chemotherapy.
- Predict relapse months before it appears on radiological scans.
- Evaluate the effectiveness of the current treatment regimen.
Book MRD Monitoring Test in Saudi Arabia | Lahalak Medical Platform
Advanced ctDNA technology monitors minimal residual cancer cells with high precision, enabling early detection of relapse before clinical symptoms appear. This ensures timely medical intervention and personalized treatment strategies for better patient outcomes.
Scientific name: Molecular Residual Disease (MRD) Monitoring
A serial ctDNA blood test designed to detect minimal residual disease (MRD). It monitors treatment response and identifies early relapse signs long before they are visible on conventional imaging or clinical scans.
Service type
Advanced laboratory test
Duration
15-20 minutes
Fasting
Fasting is not required
Included Services
- Blood sample collection
- ctDNA sequencing analysis
- Detailed medical report
Medical Service Information
Target Groups
- Cancer survivors monitoring their remission status.
- Patients undergoing active chemotherapy or radiation.
- Solid tumor cases requiring precise and continuous follow-up.
Benefits of the Technology
- Extreme precision in monitoring tumor DNA fragments.
- Non-invasive procedure using a simple blood sample (Liquid Biopsy).
- Gaining critical time for early intervention if the disease recurs.
Conditions & Notices
- Periodic testing recommended by the oncologist
- Provide previous medical reports regarding the tumor type
Medical services you might also like
